“We were extremely pleased to see preliminary evidence of improved vascular health with INZ-701 treatment in adults with ABCC6 Deficiency, providing strong support for further clinical development in this disease,” said Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme. “We found that children with ABCC6 Deficiency are at high risk for neurological and visual impairment and represent the most pressing unmet need in this disease, substantially expanding the addressable population beyond impacted adults. We look forward to working with regulators to establish a path to approval for our ABCC6 Deficiency program, as well as presenting additional data from current trials in our calciphylaxis and ENPP1 Deficiency programs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Inozyme reports inducement grants under Nasdaq listing rule
- Inozyme management to meet with Piper Sandler
- Inozyme price target lowered to $14 from $16 at BofA